Antibody;100UG;IgG1/kappa;Recognizes Bevacizumab specifically, no cross reactivity with other humanized antibodies.;Mouse monoclonal antibody is produced from a hybridoma resulting from fusion of SP2/0 myeloma and B-lymphocytes obtained from a mouse immunized with Bevacizumab F(ab')2.; ;Anti-Bevacizumab Antibodies bridging ELISA for Anti-Drug Antibody (ADA) assay development. Immobilized bevacizumab at 0.05 g/mL, add increasing concentrations of Anti-Bevacizumab Antibodies (recommended for neutralizing assay) (Cat. No. BEB-Y12, 10% human serum) and then add biotinylated bevacizumab at 5 g/mL. Detection was performed using HRP-conjugated streptavidin with a sensitivity of 62 ng/mL. ;Demonstration of the specificity of Anti-Bevacizumab Antibodies (recommended for neutralizing assay) (Cat. No. BEB-Y12) to the bevacizumab.;Anti-Bevacizumab Antibodies (recommended for neutralizing assay) (mouse IgG1, Cat. No. BEB-Y12) captured on CM5 chip via anti-mouse antibodies surface, can
